NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free RCUS Stock Alerts $16.90 -0.56 (-3.21%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$16.87▼$17.5150-Day Range$14.59▼$19.0552-Week Range$12.95▼$25.47Volume525,096 shsAverage Volume587,427 shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$41.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcus Biosciences alerts: Email Address Arcus Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside144.1% Upside$41.25 Price TargetShort InterestBearish16.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 15 Articles This WeekInsider TradingSelling Shares$1.01 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.02) to ($3.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 starsMedical Sector755th out of 923 stocksPharmaceutical Preparations Industry349th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArcus Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Arcus Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.36% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 13.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 1.9 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Arcus Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,014,779.00 in company stock.Percentage Held by Insiders12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.02) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcus Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Arcus Biosciences Stock (NYSE:RCUS)Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More RCUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCUS Stock News HeadlinesMay 16 at 2:00 AM | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 15 at 9:13 PM | markets.businessinsider.comBuy Rating on Arcus Biosciences: Unique Anti-TIGIT Antibody and Promising Cancer Trials Fuel OptimismMay 15 at 3:38 AM | seekingalpha.comArcus Biosciences: A Preview Of Their Outlook Ahead Of ASCOMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcus Biosciences Based on Promising Efficacy and Safety Profile of DomvanalimabMay 13, 2024 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Arcus Biosciences (NYSE:RCUS)May 13, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Arcus Biosciences, Inc. Issued By Wedbush (NYSE:RCUS)May 12, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 12, 2024 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Trading Up 9.3%May 11, 2024 | americanbankingnews.comWedbush Weighs in on Arcus Biosciences, Inc.'s Q1 2025 Earnings (NYSE:RCUS)May 10, 2024 | finance.yahoo.comArcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024May 10, 2024 | finance.yahoo.comArcus Biosciences First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Shares Gap Up Following Strong EarningsMay 9, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)May 9, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsMay 9, 2024 | finance.yahoo.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comArcus Biosciences: Holding Steady Amidst Progress and UncertaintiesMay 9, 2024 | finance.yahoo.comArcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 8, 2024 | investorplace.comRCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comArcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline UpdateMay 7, 2024 | marketwatch.comPrecision BioSciences Gets FDA Fast Track Designation for Program to Treat Genetic Urea Cycle Disorder in NewbornsMay 2, 2024 | businesswire.comArcus Biosciences to Participate in the Bank of America Healthcare Conference 2024May 2, 2024 | markets.businessinsider.comPromising Outlook for Arcus Biosciences Anchored by Strong Clinical Trials and Strategic Market PositioningApril 24, 2024 | businesswire.comArcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingApril 23, 2024 | businesswire.comArcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateApril 18, 2024 | bizjournals.comEli Lilly subsidiary ends lucrative collaboration with Durham biotechSee More Headlines Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/18/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees577Year FoundedN/APrice Target and Rating Average Stock Price Target$41.25 High Stock Price Target$70.00 Low Stock Price Target$23.00 Potential Upside/Downside+144.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-307,000,000.00 Net Margins-97.47% Pretax Margin-95.78% Return on Equity-40.98% Return on Assets-19.25% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio5.22 Sales & Book Value Annual Sales$117 million Price / Sales13.14 Cash FlowN/A Price / Cash FlowN/A Book Value$7.77 per share Price / Book2.18Miscellaneous Outstanding Shares90,950,000Free Float79,766,000Market Cap$1.54 billion OptionableOptionable Beta0.91 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Terry J. Rosen Ph.D. (Age 64)Co-Founder, Chairman & CEO Comp: $756.11kDr. Juan Carlos Jaen Ph.D. (Age 66)Co- Founder & President Comp: $931.14kMr. Robert C. Goeltz II (Age 51)Principal Financial Officer & CFO Comp: $745.29kMs. Jennifer A. Jarrett M.B.A. (Age 53)Chief Operating Officer Comp: $925.29kDr. Dimitry S.A. Nuyten M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700.34kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Alexander Azoy (Age 48)VP of Finance & Principal Accounting Officer Dr. Jonathan Yingling Ph.D. (Age 55)Chief Scientific Officer More ExecutivesKey CompetitorsSpyre TherapeuticsNASDAQ:SYRETaro Pharmaceutical IndustriesNYSE:TAROSupernus PharmaceuticalsNASDAQ:SUPNKura OncologyNASDAQ:KURALigand PharmaceuticalsNASDAQ:LGNDView All CompetitorsInsiders & InstitutionsComerica BankSold 2,754 shares on 5/17/2024Ownership: 0.025%Walleye Trading LLCSold 30,400 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 2,831 shares on 5/16/2024Ownership: 0.054%Price T Rowe Associates Inc. MDBought 1,906 shares on 5/15/2024Ownership: 0.038%Vanguard Group Inc.Bought 110,528 shares on 5/10/2024Ownership: 5.268%View All Insider TransactionsView All Institutional Transactions RCUS Stock Analysis - Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCUS shares. View RCUS analyst ratings or view top-rated stocks. What is Arcus Biosciences' stock price target for 2024? 8 analysts have issued twelve-month price objectives for Arcus Biosciences' shares. Their RCUS share price targets range from $23.00 to $70.00. On average, they expect the company's stock price to reach $41.25 in the next twelve months. This suggests a possible upside of 144.1% from the stock's current price. View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts. How have RCUS shares performed in 2024? Arcus Biosciences' stock was trading at $19.10 at the beginning of the year. Since then, RCUS shares have decreased by 11.5% and is now trading at $16.90. View the best growth stocks for 2024 here. Are investors shorting Arcus Biosciences? Arcus Biosciences saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 6,840,000 shares, a decrease of 17.1% from the March 31st total of 8,250,000 shares. Based on an average daily volume of 819,200 shares, the short-interest ratio is presently 8.3 days. Approximately 14.5% of the shares of the company are short sold. View Arcus Biosciences' Short Interest. When is Arcus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our RCUS earnings forecast. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) posted its earnings results on Wednesday, May, 8th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.92. The firm earned $145 million during the quarter, compared to analyst estimates of $28.77 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 40.98% and a negative net margin of 97.47%. The firm's revenue was up 480.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.09) earnings per share. What ETFs hold Arcus Biosciences' stock? ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC) and iShares Genomics Immunology and Healthcare ETF (IDNA).Invesco S&P SmallCap Health Care ETF (PSCH). What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.27%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.75%), Principal Financial Group Inc. (0.32%), Nordea Investment Management AB (0.29%), California State Teachers Retirement System (0.05%) and Assenagon Asset Management S.A. (0.04%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen and William Grossman. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:RCUS) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
